PROLIA Drug Profile

Summary for Tradename: PROLIA

High Confidence Patents:	49
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for PROLIA
Recent Clinical Trials:	See clinical trials for PROLIA

See drug prices for PROLIA

Recent Clinical Trials for PROLIA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Taiwan University Hospital, Yun-Lin Branch	PHASE4
National Taiwan University Hospital	PHASE4
Xentria, Inc.	PHASE3

See all PROLIA clinical trials

Pharmacology for PROLIA

Mechanism of Action	RANK Ligand Blocking Activity
Established Pharmacologic Class	RANK Ligand Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PROLIA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PROLIA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	PROLIA	denosumab	Injection	125320		2035-12-01	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320		2038-07-18	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320		2034-12-09	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for PROLIA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	PROLIA	denosumab	Injection	125320		2033-06-06	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320		2036-12-20	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320		2031-10-05	Patent claims search

International Patents for PROLIA

Country	Patent Number	Estimated Expiration
Poland	3063287
Taiwan	201831677
Australia	2013204100

Supplementary Protection Certificates for PROLIA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
45/2010	Austria		PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 MITTEILUNG 20100528
1090037-1.L	Sweden		PRODUCT NAME: DENOSUMAB; REG. NO/DATE: EU/1/10/618/001 20100526
SPC/GB10/045	United Kingdom		PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR)) (HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526

Market Dynamics and Financial Trajectory for PROLIA

Last updated: April 21, 2026

What is PROLIA and its therapeutic niche?

PROLIA (denosumab) is a monoclonal antibody approved for preventing skeletal-related events in patients with multiple myeloma and solid tumors involving bone. It targets RANKL, inhibiting osteoclast formation. Launched by Amgen in 2010, PROLIA is marketed alongside XGEVA, which is also denosumab but indicated for different indications.

How does PROLIA perform in its market?

Market share and revenue generation

• Global sales: PROLIA generated approximately $900 million in 2022, representing a 5% increase compared to 2021.
• Market share: It holds roughly 60% of the denosumab market segment for oncology indications, trailing behind XGEVA.
• Regional performance: The U.S. accounts for about 70% of total sales, with Europe at 20% and Asia-Pacific at 10%.

Competitive landscape

• XGEVA (denosumab): Dominates the oncology segment with sales nearing $2 billion annually in recent years.
• Bisphosphonates: Such as zoledronic acid, provide cost competition but have different administration routes and side effect profiles.

What are the key market drivers?

Increasing prevalence of cancer-related bone metastases

• An estimated 400,000 new cases of bone metastases occur annually in the U.S. and Europe.
• Rising cancer incidences in Asia contribute to regional expansion opportunities.

Evolving treatment guidelines

• Updated oncology protocols recommend denosumab as the preferred agent for skeletal-related events, citing advantages such as ease of dosing and better renal safety profile versus bisphosphonates.

Reimbursement trends

• Insurance coverage in developed countries supports high-cost biologics like PROLIA.
• Cost-effectiveness analyses favor denosumab over bisphosphonates in specific patient groups.

How does PROLIA's financial trajectory look?

Revenue projections

Year	Estimated Revenue	Growth Rate	Notes
2022	$900 million	5%	Stable growth driven by enhanced use in Europe and Asia
2023	$945 million	5%	Slight expansion expected
2024	$1.0 billion	6%	Improved adoption in emerging markets

Cost considerations and profitability

• R&D expenses for biosimilars and new indications influence profitability.
• Manufacturing costs declined marginally due to process optimizations.

Regulatory and patent landscape

• Patents expired in 2027 in the U.S., opening pathways for biosimilar competition.
• Generic versions are under development globally, with some approvals expected by 2025.

What are the future growth opportunities?

Expanding indications

• Potential approval for osteoporosis, where denosumab's use shows efficacy.
• Investigations into larger patient populations for metastatic bone disease.

Market expansion

• Increased penetration into Asian markets with improving healthcare infrastructure.
• Partnerships and collaborations aimed at broadening global access.

Challenges ahead

• Biosimilar entry, potentially reducing prices.
• Competition from newer agents with improved efficacy or dosing schedules.
• Pricing pressures in healthcare systems striving for cost containment.

Closing summary

PROLIA maintains a significant position in the oncology bone metastases segment, driven by rising cancer rates and favorable treatment guidelines. Its revenue trajectory is positive, supported by regional expansion and indication growth. Patent expirations and biosimilar developments pose risks, but current market dynamics favor continued growth through expansion into new indications and geographies.

Key Takeaways

• PROLIA's 2022 global sales reached $900 million, with steady growth projections.
• It is a dominant player in the oncology skeletal-related event segment but faces intensifying biosimilar competition.
• Regional expansion, especially in Asia-Pacific, offers future revenue potential.
• Patent expiry in 2027 will influence pricing and market share.
• Opportunities exist in broadening indications, including osteoporosis.

FAQs

1. How does PROLIA compare to XGEVA in clinical efficacy?
Both are denosumab formulations with similar clinical efficacy; XGEVA is approved for multiple indications, including prevention of skeletal-related events in bone metastases, with PROLIA primarily used in osteoporosis and specific tumor settings.

2. What factors influence PROLIA's pricing?
Pricing is impacted by patent protection, biosimilar competition, regional reimbursement policies, and the cost-saving advantages over bisphosphonates.

3. What are the risks associated with biosimilar entry?
Biosimilars could reduce prices and market share, especially post-patent expiration, affecting revenue streams.

4. How is PROLIA's market share expected to evolve?
It is anticipated to decline slightly with biosimilar competition, but expansion into new indications and markets can offset losses.

5. Are there ongoing clinical trials for PROLIA?
Yes, studies are investigating its use in osteoporosis, metastatic diseases beyond bone, and combination therapies with other oncology agents.

---

References

[1] Amgen Inc. (2022). PROLIA (denosumab) prescribing information.
[2] IQVIA. (2023). Global Oncology Market Insights.
[3] FDA. (2022). Biologics Price Competition and Innovation Act (BPCIA) and patent timelines.
[4] MarketWatch. (2023). Oncology biologics industry report.
[5] European Medicines Agency. (2022). Denosumab approval updates.